NCT06110130View on ClinicalTrials.gov

Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

PHASE4RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 2, 2024

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2028

Conditions
Chronic Kidney Diseases
Interventions
DRUG

Empagliflozin 10 MG

Take Empagliflozin 10 mg orally daily for 4 months

DRUG

Placebo

Take Placebo 10 mg orally daily for 4 months

Trial Locations (1)

20422

RECRUITING

Washington DC Veterans Affairs Medical Center (688), Washington D.C.

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Washington D.C. Veterans Affairs Medical Center

FED